Black tea reduces uric acid and C-reactive protein levels in humans susceptible to cardiovascular diseases

Toxicology

Volumn 278, Issue 1, 2010, Pages 68-74

  Bahorun, Theeshan ^a   Luximon Ramma, Amitabye ^a   Gunness, Teeluck K ^b   Sookar, Dharmendra ^b   Bhoyroo, Satar ^b   Jugessur, Rabindranath ^b   Reebye, Deshmukh ^b   Googoolye, Kreshna ^a   Crozier, Alan ^c   Aruoma, Okezie I ^d  

^a UNIVERSITY OF MAURITIUS   (Mauritius)

^b Cardiac Centre   (Mauritius)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d TOURO COLLEGE   (United States)

Author keywords

Black tea and statin therapy; C reactive protein; Cardioprotection and cardiovascular diseases; Functional foods; Inflammation; Tea polyphenols and biomarkers; Uric acid

Indexed keywords

C REACTIVE PROTEIN; URIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DIET SUPPLEMENTATION; FEMALE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TEA; THEA NIGRA; URIC ACID BLOOD LEVEL;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TEA; URIC ACID;

CAMELLIA SINENSIS;

EID: 78149406720     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.11.024     Document Type: Article

References (58)

1. Bagnati M., Perugini C., Cau C., Bordone R., Albano E., Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem. J. 1999, 340:143-152.
2. Bo S., Cavallo-Perin P., Gentile L., Repetti E., Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur. J. Clin. Invest. 2001, 31:318-321.
3. Boogaerts M.A., Hammerschmidt D.E., Roelant C., Verwilghen R.L., Jacob H.S. Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury. Thromb. Haemost. 1983, 50:576-580.
4. Bos M.J., Koudstaal P.J., Hofman A., Witteman J.C.M., Breteler M.M.B. Uric acid is a riskfactor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006, 37:1503-1507.
5. Brodov Y., Behar S., Goldenberg I., Boyko V., Chouraqui P. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] Study). Am. J. Cardiol. 2009, 104:194-198.
6. Carr S.C., Farb A., Pearce W.H., Virmani R., Yao J.S. Activated inflammatory cells are associated with plaque rupture in carotid artery stenosis. Surgery 1997, 122:757-763.
7. De Bacquer D., Clays E., Delanghe J., De Backer G. Epidemiological evidence for an association between habitual tea consumption and markers of chronic inflammation. Atherosclerosis 2006, 189:428-435.
8. de Mejia E.G., Ramirez-Mares M.V., Puangpraphant S. Bioactive components of tea: cancer, inflammation and behavior. Brain Behav. Immun. 2009, 23:721-731.
9. Falasca G.F., Ramachandrula A., Kelley K.A., O'Connor C.R., Reginato A.J. Superoxide anion production and phagocytosis of crystals by cultured endothelial cells. Arthritis Rheum. 1993, 36:105-116.
10. Ferroni P., Basili S., Paoletti V., Davi{dotless} G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr. Metab. Cardiovasc. Dis. 2006, 16:222-233.
11. Frazier L., Vaughn W.K., Willerson J.T., Ballentyne C.M., Boerwinkle E. Inflammatory protein levels and depression screening after coronary stenting predict major adverse coronary events. Biol. Res. Nurs. 2009, 11:163-173.
12. Huang M.T., Liu Y., Ramji D., Lo C.Y., Ghai G., Dushenkov S., Ho C.T. Inhibitory effects of black tea theaflavin derivatives on 12-otetradecanoylphorbol-13-acetate-induced inflammation and arachidonic acid metabolism in mouse ears. Mol. Nutr. Food Res. 2006, 50:115-122.
13. Kannel W.B., Neaton J.D., Wentworth D., Thomas H.E., Stamler J., Hulley S.B., Kjelsberg M.O. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for MRFIT. Multiple Risk Factor Intervention Trial. Am. Heart. J. 1986, 112:825-836.
14. Kanellis J., Feig D.I., Johnson R.J. Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed. Nephrology (Carlton) 2004, 9:394-399.
15. Kim H.J., Park S.H., Park S.Y., Moon U.Y., Lee B.D., Yoon S.H., Lee J.G., Baek S.J., Yoon J.H. Epigallocatechin-3-gallate inhibits interleukin-1 β-induced MUC5AC gene expression and MUC5AC secretion in normal human nasal epithelial cells. J. Nutr. Biochem. 2008, 19:536-544.
16. Koenig W., Sund M., Frohlich M., Fischer H.-G., Löwel H., Döring A., Hutchinson W.L., Pepys M.B. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring Trends and Determinants in Cardiovascular Disease) Augsberg Cohort study, 1984 to 1992. Circulation 1999, 99:237-242l.
17. Kohn P.M., Prozon G.B. Hyperuricemia: relationship to hypercholesterolemia and acute myocardial infarction. J. Am. Med. Assoc. 1959, 170:1909-1915.
18. Langley-Evans S.C. Consumption of black tea elicits an increase in plasma antioxidant potential in humans. Int. J. Food. Sci. Nutr. 2000, 51:309-315.
19. Li X., Lun X. Study on correlation between C-reactive protein and gestational diabetes mellitus. J. Nanjing Med. Univ. 2007, 21:382-385.
20. Lippi G., Montagnana M., Franchini M., Favaloro E.J., Targher G. The paradoxical relationship between serum uric acid and cardiovascular diseases. Clin. Chim. Acta 2008, 392:1-7.
21. Lippi G., Targher G., Montagnana M., Salvagno G.L., Guidi G.C. Hyperuriceamia is associated with increased C-reactive protein concentrations in a large cohort of unselected outpatients. Nutr. Metab. Cardiovasc. Dis. 2008, 18:e41-e42.
22. Macchi C., Molino-Lova R., Polcaro P., Guarucci L., Lauretani F., Cecchi F., Bandinelli S., Guralnik J.M., Ferrucci L. Higher circulating levels of uric acid are prospectively associated with better muscle function in older persons. Mech. Ageing Dev. 2008, 129:522-527.
23. Manson J.E., Tosteson H., Ridker P.M., Satterfield S., Hebert P., O'Connor G.T., Buring J., Hennekens C.H. The primary prevention of myocardial infarction. N. Engl. J. Med. 1992, 326:1406-11406.
24. Masuo K., Kawaguchi H., Mikami H., Ogihara T., Tuck M.L. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003, 42:474-480.
25. Mazzone T., Chait A., Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
26. Muntner P., Mann D., Razzouk L., Klarenbach S., Manns B., Tonelli M., Farkouh M.E. Is measuring C-reactive protein useful for guiding treatment in women ≥60 years and men ≥50 years of age. Am. J. Cardiol. 2009, 104:354-358.
27. Nag-Chaudhuri A.K., Karmakar S., Roy D., Pal S., Pal M., Sen T. Antiinflammatory activity of Indian black tea (Sikkim variety). Pharmacol. Res. 2005, 51:169-175.
28. Nakanishi N., Okamoto M., Yoshida H., Matsuo Y., Suzuki K., Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur. J. Epidemiol. 2003, 18:523-530.
29. Nan H., Qiao Q., Soderberg S., Pitkaniemi J., Zimmet P., Shaw J., Alberti G., Uusitalo U., Pauvaday V., Chitson P., Tuomilehto J. Serum uric acid and incident diabetes in Mauritian Indian and Creole populations. Diabetes Res. Clin. Pract. 2008, 80:321-327.
30. Navarro-Perán E., Cabezas-Herrera J., Sánchez-del-Campo L., García-Cánovas F., Rodríguez-López J.N. The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-κB suppression. Inflamm. Res. 2008, 57:472-478.
31. Pasterkamp G., Schoneveld A.H., van der Wal A.C., Hijnen D.J., van Wolveren W.J., Plomp S., Teepen H.L., Borst C. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler. Thromb. Vasc. Biol. 1999, 19:54-58.
32. Patetsios P., Rodino W., Wisselink W., Bryan D., Kirwin J.D., Panatta T.F. Identification of uric acid in aortic aneurysms and atherosclerotic artery. Ann. N.Y. Acad. Sci. 1996, 800:243-245.
33. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000, 342:836-843.
34. Ridker P.M. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am. J. Cardiol. 2003, 92:17-22.
35. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
36. Rouanet J.M., Décordé K., Del Rio D., Auger C., Borges G., Cristol J.-P., Lean M.E.J., Crozier A. Berry juices, teas, antioxidants and the prevention of atherosclerosis in hamsters. Food Chem. 2010, 118:266-271.
37. Roy D.K., Kumar K.T.M.S., Karmakar S., Pal S., Samanta S.K., Adhikari D., Sen T. Pharmacological studies on Indian black tea (leaf variety) in acute and chronic inflammatory conditions. Phytother. Res. 2008, 22:814-819.
38. Rufail M.L., Ramage S.C., van Antwerpen R. C-reactive protein inhibits in vitro oxidation of low-density lipoprotein. FEBS Lett. 2006, 580:5155-5160.
39. Ruggiero C., Cherubini A., Miller E., Maggio M., Najjar S.S., Lauretani F., Bandinelli S., Senin U., Ferrucci L. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am. J. Cardiol. 2007, 100:115-121.
40. Ruggiero C., Cherubini A., Ble A., Bos A.J., Maggio M., Dixit V.D., Lauretani F., Bandinelli S., Senin U., Ferrucci L. Uric acid and inflammatory markers. Eur. Heart J. 2006, 27:1174-1181.
41. Sharangi A.B. Medicinal and therapeutic potentialities of tea (Camellia sinensis L.)-a review. Food Res. Int. 2009, 42:529-535.
42. Shimada K., Kawarabayashi T., Tanaka A., Fukuda D., Nakamura Y., Yoshiyama M., Takeuchi K., Sawaki T., Hosoda K., Yoshikawa J. Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease. Diabetes Res. Clin. Pract. 2004, 65:227-234.
43. Stangl V., Lorenz M., Stangl K. The role of tea and tea flavonoids in cardiovascular health. Mol. Nutr. Food Res. 2006, 50:218-228.
44. Steptoe A., Gibson E.L., Vounonvirta R., Williams E.D., Hamer M., Rycroft J.A., Erusalimsky J.D., Wardle J. The effects of tea on psychophysiological stress responsivity and post-stress recovery: a randomised double-blind trial. Psychopharmacology (Berl.) 2007, 190:81-89.
45. Strazzullo P., Puig J.G. Uric acid and oxidative stress: relative impact on cardiovascular risk. Nutr. Metab. Cardiovasc. Dis. 2007, 17:409-414.
46. Sturm G., Kollerits B., Neyer U., Ritz E. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp. Gerontol. 2008, 43:347-352. Florian Kronenberg and for the MMKD Study Group.
47. Tinahones F.J., Rubio M.A., Garrido-Sanchez L., Ruiz C., Gordillo E., Cabrerizo L., Cardona F. Green tea reduces LDL oxidizability and improves vascular function. J. Am. Coll. Nutr. 2008, 27:209-213.
48. Torzewski J., Torzewski M., Bowyer D.E., Frohlich M., Koenig W., Waltenberger J., Fitzsimmons C., Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1386-1392.
49. Torzewski M., Rist C., Mortensen R.F., Zwaka T.P., Bienek M., Waltenberger J., Koenig W., Gerd S., Hombach V., Torzewski J. C-Reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2094-2099.
50. USDA Food Composition database, 2006. http://www.nal.usda.gov/fnic/foodcomp.
51. Varilek G.W., Yang F., Lee Y.E., William J.S., Zhong Z.O., Westberry F.K., McClain C.J. Green tea polyphenol extracts attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J. Nutr. 2001, 131:2034-2039.
52. Venugopal S.K., Devaraj S., Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am. J. Pathol. 2005, 166:1265-1271.
53. Waring W.S., Conver A., Mishra Y.V., Shenkin A., Webband D.J., Maxwell S.R.J. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin. Sci. 2003, 105:425-430.
54. Wheeler D.S., Catravas J.D., Odoms K., Denenberg A., Malhotra V., Wong H.R. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1β-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J. Nutr. 2004, 134:1039-1044.
55. Widlansky M.E., Duffy S.J., Hamburg N.M., Gokce N., Warden B.A., Wiseman S., Keaney J.F., Balz Frei B., Vita J.A. Effects of black tea consumption on plasma catechins and markers of oxidative stress and inflammation in patients with coronary artery disease. Free Radic. Biol. Med. 2005, 38:499-506.
56. Yamada H., Watanabe H. Tea polyphenols in preventing cardiovascular diseases. Cardiovasc. Res. 2007, 73:439-440.
57. Yang C.S., Lambert J.D., Hou Z., Ju J., Lu G., Hao X. Molecular targets for the cancer preventive activity of tea polyphenols. Mol. Carcinog. 2006, 45:431-435.
58. Zitnanová I., Korytár P., Aruoma O.I., Sustrová M., Garaiová I., Muchová J., Kalnovicová T., Pueschel S., Duraková Z. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?. Clin. Chim. Acta 2004, 341:139-146.